Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2021 Filed Jun 22, 2021 20:12 UTC |
Pestrikova IrinaSenior Director, Finance
|
GrantStock Option · Derivative | 75,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-042378 · doc4.xml · derivative · entry 1 Pestrikova Irina · CIK 0001868216 · Senior Director, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning June 18, 2022. Read SEC document |
| April 07, 2021 Filed Apr 7, 2021 20:08 UTC |
Thornton Michael MilosChief Technology Officer
|
SaleCommon Stock | 15,000 | $2.53 | $37,950.00 |
DisclosureSEC source: 0001209191-21-025846 · doc4.xml · nonDerivative · entry 2 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.56, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:15 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025859 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:13 UTC |
Basenese LouDirector
|
GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025853 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 16:05 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
GrantStock Options · Derivative | 50,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025842 · doc4.xml · derivative · entry 1 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:10 UTC |
Wells David R.Chief Financial Officer
|
GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025849 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 16:18 UTC |
Tokman Alexander YDirector
|
GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025866 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:16 UTC |
Harsh MichaelDirector
|
GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025861 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:11 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025850 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:08 UTC |
Thornton Michael MilosChief Technology Officer
|
GrantStock Options · Derivative | 50,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025846 · doc4.xml · derivative · entry 3 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-05 F4 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| March 29, 2021 Filed Apr 7, 2021 20:08 UTC |
Thornton Michael MilosChief Technology Officer
|
SaleCommon Stock | 18,750 | $2.37 | $44,437.50 |
DisclosureSEC source: 0001209191-21-025846 · doc4.xml · nonDerivative · entry 1 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.39, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Apr 30, 2021 20:22 UTC |
Thornton Michael MilosChief Technology Officer
|
GrantCommon Stock | 22,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029290 · doc4.xml · nonDerivative · entry 1 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,525 F1 · shares: Represents restricted stock units paid as a 2020 annual bonus by the Issuer to the Reporting Person, which fully vested upon grant. Read SEC document |
| January 28, 2021 Filed Sep 22, 2021 20:05 UTC |
Thornton Michael MilosChief Technology Officer
|
GrantCommon Stock | 22,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057234 · doc4.xml · nonDerivative · entry 1 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,525 Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 21:18 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
SaleCommon Stock | 13,696 | $1.10 | $15,065.60 |
DisclosureSEC source: 0001209191-21-003597 · doc4.xml · nonDerivative · entry 2 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,580 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 21:18 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
SaleCommon Stock | 6,304 | $1.05 | $6,619.20 |
DisclosureSEC source: 0001209191-21-003597 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,276 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 19:10 UTC |
Tokman Alexander YDirector
|
SaleCommon Stock | 10,000 | $0.90 | $9,000.00 |
DisclosureSEC source: 0001209191-21-002827 · doc4.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,857 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:11 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
SaleCommon Stock | 8,731 | $0.94 | $8,207.14 |
DisclosureSEC source: 0001209191-21-002828 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,580 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 00:15 UTC |
Wells David R.Chief Financial Officer
|
SaleCommon Stock | 34,900 | $0.90 | $31,410.00 |
DisclosureSEC source: 0001209191-21-002370 · doc4.xml · nonDerivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,003 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 00:15 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
SaleCommon Stock | 11,269 | $0.94 | $10,592.86 |
DisclosureSEC source: 0001209191-21-002371 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,311 F1 · kind: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 00:15 UTC |
Wells David R.Chief Financial Officer
|
SaleCommon Stock | 100 | $0.90 | $90.00 |
DisclosureSEC source: 0001209191-21-002370 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,903 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020. Read SEC document |
| January 04, 2021 Filed Mar 25, 2021 21:00 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-21-023038 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-04 F1 · shares: Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 04, 2021 Filed Mar 25, 2021 21:01 UTC |
Basenese LouDirector
|
GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-21-023042 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-04 F1 · shares: Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 04, 2021 Filed Mar 25, 2021 17:00 UTC |
Tokman Alexander YDirector
|
GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-21-023039 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-04 F1 · shares: Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 04, 2021 Filed Mar 25, 2021 21:00 UTC |
Harsh MichaelDirector
|
GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-21-023040 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-04 F1 · shares: Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 12:00 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
SaleCommon Stock | 25,000 | $0.73 | $18,250.00 |
DisclosureSEC source: 0001209191-20-064584 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,580 F1 · kind: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.73 to $0.75, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 07:04 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
SaleCommon Stock | 71,519 | $0.83 | $59,360.77 |
DisclosureSEC source: 0001209191-20-062113 · doc4.xml · nonDerivative · entry 1 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,091 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:01 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
SaleCommon Stock | 10,000 | $0.81 | $8,100.00 |
DisclosureSEC source: 0001209191-20-058450 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,580 F1 · kind: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.83, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| October 22, 2020 Filed Oct 26, 2020 21:14 UTC |
Basenese LouDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-20-055831 · doc4.xml · derivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-10-22 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning on October 22, 2021. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 11:22 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
SaleCommon Stock | 10,000 | $0.72 | $7,200.00 |
DisclosureSEC source: 0001209191-20-053429 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,580 F1 · shares: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.72 to $0.74, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 12:00 UTC |
DIGIANDOMENICO ANTHONYDirector
|
OtherWarrants · Derivative | 100,503 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-20-043430 · doc4.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,503 shares Expires 2024-12-11 Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 12:00 UTC |
DIGIANDOMENICO ANTHONYDirector
|
OtherCommon Stock | 100,503 | $0.87 | $87,437.61 |
DisclosureSEC source: 0001209191-20-043430 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,012 F1 · balance_after: Included unvested restricted stock units. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 20:06 UTC |
Thornton Michael MilosChief Technology Officer
|
OtherWarrants · Derivative | 26,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-20-042615 · doc4.xml · derivative · entry 2 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,252 Underlying: Common Stock · 26,000 shares Expires 2024-12-11 Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 20:06 UTC |
Thornton Michael MilosChief Technology Officer
|
OtherCommon Stock | 26,000 | $0.87 | $22,620.00 |
DisclosureSEC source: 0001209191-20-042615 · doc4.xml · nonDerivative · entry 1 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,710 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 08:21 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
OtherWarrants · Derivative | 2,874 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-20-038680 · doc4.xml · derivative · entry 2 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,152 Underlying: Common Stock · 2,874 shares Expires 2024-12-11 Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 08:21 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
OtherCommon Stock | 2,874 | $0.87 | $2,500.38 |
DisclosureSEC source: 0001209191-20-038680 · doc4.xml · nonDerivative · entry 1 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,610 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 12:22 UTC |
Wells David R.Chief Financial Officer
|
OtherWarrants · Derivative | 5,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-20-038681 · doc4.xml · derivative · entry 3 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,051 Underlying: Common Stock · 5,000 shares Expires 2024-12-11 Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 12:22 UTC |
Wells David R.Chief Financial Officer
|
OtherCommon Stock | 5,000 | $0.87 | $4,350.00 |
DisclosureSEC source: 0001209191-20-038681 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,003 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 12:23 UTC |
Harsh MichaelDirector
|
OtherWarrants · Derivative | 5,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-20-038682 · doc4.xml · derivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,056 Underlying: Common Stock · 5,000 shares Expires 2024-12-11 Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 12:23 UTC |
Harsh MichaelDirector
|
OtherCommon Stock | 5,000 | $0.87 | $4,350.00 |
DisclosureSEC source: 0001209191-20-038682 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,243 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 11:27 UTC |
DIGIANDOMENICO ANTHONYDirector
|
PurchaseCommon Stock | 5,000 | $0.92 | $4,600.00 |
DisclosureSEC source: 0001209191-20-035185 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,509 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.94, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 07:36 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
ConversionSeries A Convertible Preferred Stock · Derivative | 4.372 | $1,143.68 Strike: $0.87 | $5,000.17 |
DisclosureSEC source: 0001209191-20-035436 · doc4.xml · derivative · entry 2 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A Convertible Preferred Stock has no expiration date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 07:36 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
ConversionCommon Stock | 5,175 | $0.87 | $4,502.25 |
DisclosureSEC source: 0001209191-20-035436 · doc4.xml · nonDerivative · entry 1 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:38 UTC |
Wells David R.Chief Financial Officer
|
ConversionSeries A Convertible Preferred Stock · Derivative | 8.744 | $1,143.68 Strike: $0.87 | $10,000.34 |
DisclosureSEC source: 0001209191-20-035438 · doc4.xml · derivative · entry 3 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A Convertible Preferred Stock has no expiration date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:38 UTC |
Wells David R.Chief Financial Officer
|
ConversionCommon Stock | 10,350 | $0.87 | $9,004.50 |
DisclosureSEC source: 0001209191-20-035438 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:39 UTC |
Harsh MichaelDirector
|
ConversionSeries A Convertible Preferred Stock · Derivative | 9.618 | $1,143.68 Strike: $0.87 | $10,999.91 |
DisclosureSEC source: 0001209191-20-035439 · doc4.xml · derivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A Convertible Preferred Stock has no expiration date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:39 UTC |
Harsh MichaelDirector
|
ConversionCommon Stock | 11,386 | $0.87 | $9,905.82 |
DisclosureSEC source: 0001209191-20-035439 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:37 UTC |
Thornton Michael MilosChief Technology Officer
|
ConversionSeries A Convertible Preferred Stock · Derivative | 43.719 | $1,143.68 Strike: $0.87 | $50,000.55 |
DisclosureSEC source: 0001209191-20-035437 · doc4.xml · derivative · entry 2 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A Convertible Preferred Stock has no expiration date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:37 UTC |
Thornton Michael MilosChief Technology Officer
|
ConversionCommon Stock | 51,747 | $0.87 | $45,019.89 |
DisclosureSEC source: 0001209191-20-035437 · doc4.xml · nonDerivative · entry 1 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 10:27 UTC |
Basenese LouDirector
|
PurchaseCommon Stock | 10,000 | $0.90 | $9,000.00 |
DisclosureSEC source: 0001209191-20-033102 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,068 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 28, 2020 Filed May 29, 2020 10:49 UTC |
DIGIANDOMENICO ANTHONYDirector
|
PurchaseCommon Stock | 5,000 | $0.90 | $4,500.00 |
DisclosureSEC source: 0001209191-20-032827 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,509 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.88 to $0.94, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. F3 · balance_after: The balance reflects an adjustment to correct a computational error in column 5 of the reporting person's Form 4 filed December 11, 2019, which stated 199,226 but should have stated 218,652. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.